ArticleJournal of the American College of Cardiology2017
Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology.
Article in Journal of the American College of Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Determining optimal strategies for primary prevention of cardiovascular disease: a synopsis of an evidence synthesis study.Health technology assessment (Winchester, England) · 2025 · on this mapPooled it
- Trial
- Trial
- Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.World journal of gastroenterology · 2021Trial
- A controlled trial of dissemination and implementation of a cardiovascular risk reduction strategy in small primary care practices.Health services research · 2020Trial
- Strengthening community-clinical linkages to reduce cardiovascular disease risk in rural NC: feasibility phase of the CHANGE study.BMC public health · 2020Trial
- Use of a Metabolic Syndrome SeverityDiabetes care · 2018Trial
- Article
- Observational
- Systematic examination of the PREVENT equations for cardiovascular disease risk.American journal of preventive cardiology · 2026Article
- Combining Genomics With Lipid and Inflammatory Biomarkers to Predict Coronary Artery Disease Risk: UK Biobank Study.Journal of the American College of Cardiology · 2026Article
- Performance of Cardiovascular Disease (CVD) Risk Assessment Tools in Clinical Practice - Agreement Between Different CVD Risk Scores Among Patients Attending NCD Clinic in a Tertiary Care Setting: A Prospective Observational Study.International journal of preventive medicine · 2026Article
- Sex differences in the progression of cardiovascular-kidney-metabolic syndrome.European heart journal open · 2025Article
- ALADYNOULLI: A Bayesian approach to disease progression modeling for genomic discovery and clinical prediction.medRxiv : the preprint server for health sciences · 2025Article
- Disparities in Cardiovascular Disease in Women with Adverse Pregnancy Outcomes.medRxiv : the preprint server for health sciences · 2025Article
- Cumulative remnant cholesterol and major adverse cardiovascular events among adults with type 2 diabetes.American journal of preventive cardiology · 2025Article
- Management recommendations to reduce cardiac risk in chronic epilepsy.Epilepsy & behavior reports · 2025Review
- Intensive postpartum antihypertensive treatment (IPAT) and healthy lifestyle education: Study protocol for a pilot randomized controlled trial for patients with hypertensive disorders of pregnancy.Contemporary clinical trials · 2024Article
- Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions.European journal of preventive cardiology · 2024Article
- Low-dose aspirin, maternal cardiometabolic health, and offspring respiratory health 9 to 14 years after delivery: Findings from the EAGeR Follow-up Study.Paediatric and perinatal epidemiology · 2024Article
Corrections and comments
- Erratum issuedCorrection.2017
Authors and funding
9 authors.
Funding
Abstract
The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes-the leading causes of mortality-through several public health and healthcare strategies by 2017. The American Heart Association and American College of Cardiology support the program. The Cardiovascular Risk Reduction Model was developed by Million Hearts and the Center for Medicare & Medicaid Services as a strategy to assess a value-based payment approach toward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implementing cardiovascular preventive strategies to manage the "ABCS" (aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smoking cessation). The purpose of this special report is to describe the development and intended use of the Million Hearts Longitudinal ASCVD Risk Assessment Tool. The Million Hearts Tool reinforces and builds on the "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk" by allowing clinicians to estimate baseline and updated 10-year ASCVD risk estimates for primary prevention patients adhering to the appropriate ABCS over time, alone or in combination. The tool provides updated risk estimates based on evidence from high-quality systematic reviews and meta-analyses of the ABCS therapies. This novel approach to personalized estimation of benefits from risk-reducing therapies in primary prevention may help target therapies to those in whom they will provide the greatest benefit, and serves as the basis for a Center for Medicare & Medicaid Services program designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.